高级检索
陆建伟. 5-Fu持续静脉输注联合奥曲肽治疗晚期原发性肝癌的多中心临床研究[J]. 实用临床医药杂志, 2003, (4): 289-292. DOI: 10.3969/j.issn.1672-2353.2003.04.001
引用本文: 陆建伟. 5-Fu持续静脉输注联合奥曲肽治疗晚期原发性肝癌的多中心临床研究[J]. 实用临床医药杂志, 2003, (4): 289-292. DOI: 10.3969/j.issn.1672-2353.2003.04.001
shu
MULTI-CENTER CLINICAL TRAIL OF 5-Fu CONTINUOUS INTRAVENOUS INFUSION COMBINED WITH OCTREOTIDE IN THE TREATMENT OF ADVANCED PRIMARY HEPATIC CANCER[J]. Journal of Clinical Medicine in Practice, 2003, (4): 289-292. DOI: 10.3969/j.issn.1672-2353.2003.04.001
Citation: MULTI-CENTER CLINICAL TRAIL OF 5-Fu CONTINUOUS INTRAVENOUS INFUSION COMBINED WITH OCTREOTIDE IN THE TREATMENT OF ADVANCED PRIMARY HEPATIC CANCER[J]. Journal of Clinical Medicine in Practice, 2003, (4): 289-292. DOI: 10.3969/j.issn.1672-2353.2003.04.001
shu

5-Fu持续静脉输注联合奥曲肽治疗晚期原发性肝癌的多中心临床研究

MULTI-CENTER CLINICAL TRAIL OF 5-Fu CONTINUOUS INTRAVENOUS INFUSION COMBINED WITH OCTREOTIDE IN THE TREATMENT OF ADVANCED PRIMARY HEPATIC CANCER

    摘要
  • 摘要: 目的评价5-Fu持续静脉输注联合奥曲肽治疗晚期原发性肝癌(PHC)的疗效、对生活质量的改善及其耐受性.方法治疗组58例给予奥曲肽0.1mg,皮下注射,每8 h1次;5-Fu 0.25 g/(m2@d),深静脉24 h持续输注,使用时间均为第1～21天;对照组34例给予5-Fu(用法同治疗组),PDD6 mg/(m2@d)静脉滴注,每周用5 d,连用3周.2组均每4周为1周期.结果2组临床受益率(PR+NC)分别为59.3%和41.2%,无统计学差异.治疗组腹痛、腹胀、纳差、乏力症状改善好于对照组,腹胀和纳差症状改善明显高于对照组(P＜0.05).治疗组42.6%KS评分提高,对照组26.5%,无统计学差异.2组毒副作用主要表现为Ⅰ、Ⅱ度血液学毒性和胃肠道反应,治疗组的腹泻和口腔炎发生率低于对照组.结论奥曲肽联合5-Fu持续静脉输注对晚期PHC有一定的疗效,对减轻晚期患者的症状和改善生活质量有较好作用.

     

    • HTML全文
    • 参考文献(10)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回